Form 4: Director John T. Curnutte Receives Pliant Therapeutics Grant

Pliant Therapeutics director John T. Curnutte was granted 70,000 stock options as part of his compensation package.

Summary

• Director John T. Curnutte was granted 70,000 stock options to purchase common stock in Pliant Therapeutics, Inc.
• The options have an exercise price of $1.14 per share.
• The grant date for these options is June 11, 2026.
• The options are subject to a vesting schedule spanning from October 2026 through June 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on the director's continued service to satisfy vesting requirements.

Future Outlook

The filing does not provide a general corporate outlook, but outlines the vesting schedule for the director's options through June 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of key talent.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices for mid-cap biotech firms.
• The grant size is typical for non-employee director compensation packages in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of 25% of options on October 1, 2026.
• Vesting of 25% of options on January 1, 2027.
• Vesting of 25% of options on April 1, 2027.
• Final 25% vesting on the earlier of June 11, 2027 or the next annual meeting.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Form 4, Insider Trading, Stock Options, Director Compensation